[ad_1]
Korea-listed absolutely built-in CDMO, Samsung Biologics, has accomplished the acquisition of Biogen’s stake within the Samsung Bioepis three way partnership for US$2.3bn. With the completion of the primary cost of US$1bn pursuant to the phrases of the acquisition settlement, Samsung Biologics has absolutely acquired Samsung Bioepis as a completely owned subsidiary. The remaining US$1.3bn shall be made in…
[ad_2]
Source link
